港股異動 | 醫療器械股走強 愛康醫療(1789.HK)漲超7%
格隆匯5月14日丨醫療器械股走強,愛康醫療(1789.HK)、永勝醫療、春立醫療漲超7%,康基醫療漲超4%,康德萊醫械、威高股份、沛嘉醫療漲超2%。MSCI明晟近日公佈全球標準指數成分股半年度檢討結果顯示,MSCI中國小型指數新增包括愛康醫療、康基醫療、沛嘉醫療等在內的45只股份,同時剔出25只股份,所有變動將於5月27日(週四)收市後生效。高盛曾發研報指,內地骨科手術/醫療消耗品企業自去年7月以來估值大幅收縮,憂慮國家帶量採購帶來的定價壓力。該行稱,長期增長憧憬仍維持,受惠於手術程序滲透、進口替代品及新產品推出,認為股價過度調整帶來吸引切入點,將愛康醫療及康基醫療的評級由“中性”升至“買入”。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.